Search Results - "Ren, Xuehan"

Predictors of weight loss in early treated Parkinson’s disease from the NET-PD LS-1 cohort by Wills, Anne-Marie, Li, Ruosha, Pérez, Adriana, Ren, Xuehan, Boyd, James

“…Weight loss is a common symptom of Parkinson’s disease and is associated with impaired quality of life. Predictors of weight loss have not been studied in…”
Get full text

Parents’ parenting styles differences are associated with lifetime suicidal ideation: Evidence from Chinese medical college students by Gui, Zhen, Ren, Xuehan, Li, Xiao, Zhou, Chengchao, Sun, Long

“…This study aims to explore the association between parents parenting styles differences and lifetime suicidal ideation (LSI). The sample included 2598 Chinese…”
Get full text

Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale by Jagota, Priya, Srivanitchapoom, Prachaya, Petchrutchatachart, Sitthi, Singmaneesakulchai, Surat, Pisarnpong, Apichart, Lolekha, Praween, Setthawatcharawanich, Suwanna, Chairangsaris, Parnsiri, Limotai, Natlada, Mekawichai, Pawut, Panyakaew, Pattamon, Phokaewvarangkul, Onanong, Sringean, Jirada, Pitakpatapee, Yuvadee, LaPelle, Nancy, Martinez-Martin, Pablo, Ren, Xuehan, Luo, Sheng, Stebbins, Glenn T., Goetz, Christopher G., Bhidayasiri, Roongroj

“…Objective This study aims to validate the Thai translation of the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale…”
Get full text

Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change by Ren, Xuehan, Lin, Jeffrey, Stebbins, Glenn T., Goetz, Christopher G., Luo, Sheng

“…ABSTRACT Background Predicting Parkinson's disease (PD) progression may enable better adaptive and targeted treatment planning. Objective Develop a prognostic…”
Get full text

Filgotinib for the Treatment of Small Bowel Crohn’s Disease: The DIVERGENCE 1 Trial by D’Haens, Geert R., Lee, Scott, Taylor, Stuart A., Serone, Adrian, Rimola, Jordi, Colombel, Jean-Frederic, Besuyen, Robin, Gecse, Krisztina, McKevitt, Matt, Reinisch, Walter, Ren, Xuehan, Schwartz, David

Get full text

1102 Analysis of antepartum obstetric triage utilization at 24 weeks and beyond by Ren, Xuehan, Jelovsek, Eric, Luo, Sheng, Hughes, Brenna L., Reiff, Emily

Get full text

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) by Maakaron, Joseph, Asch, Adam S., Popplewell, Leslie L., Collins, Graham P., Flinn, Ian W., Ghosh, Nilanjan, Keane, Colin, Ku, Matthew, Mehta, Amitkumar, Roschewski, Mark, O'Hear, Carol, Ren, Xuehan, Villa, Bertha, Lal, Indu, Smith, Sonali M., Advani, Ranjana H.

Get full text

Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn’s Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial by Reinisch, Walter, Colombel, Jean-Frederic, D’Haens, Geert R, Rimola, Jordi, Masior, Tomasz, McKevitt, Matt, Ren, Xuehan, Serone, Adrian, Schwartz, David A, Gecse, Krisztina B

“…Abstract Background and Aims There is an unmet need in the treatment of perianal fistulising Crohn’s disease [PFCD]. This study evaluated the efficacy and…”
Get full text

Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration by Ren, Xuehan, Lin, Jeffrey, Luo, Sheng, Goetz, Christopher G., Stebbins, Glenn T., Cubo, Esther

“…We assessed differential item functioning (DIF) in the Unified Dyskinesia Rating Scale (UDysRS) to evaluate bias risk from the duration of Parkinson's Disease…”
Get full text

Abstract PO1-05-09: ASCENT-07: A phase 3, randomized, open-label study of sacituzumab govitecan versus treatment of physician’s choice in patients with HR+/HER2– inoperable, locally advanced, or metastatic breast cancer post-endocrine therapy by Rugo, Hope, Cortés, Javier, Curigliano, Giuseppe, Barrios, Carlos, Punie, Kevin, Park, Yeon, Iwata, Hiroji, Young, Alex, Ren, Xuehan, Cinar, Pelin, Jhaveri, Komal

“…Background: Approximately 70% of all breast cancer (BC) cases are hormone receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2–), with…”
Get full text

Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulizing Crohn's Disease [DIVERGENCE 2]: a Phase 2, Randomized, Placebo-Controlled Trial by Reinisch, Walter, Colombel, Jean-Frederic, D'Haens, Geert R, Rimola, Jordi, Masior, Tomasz, McKevitt, Matt, Ren, Xuehan, Serone, Adrian, Schwartz, David A, Gecse, Krisztina B

“…There is an unmet need for the treatment of perianal fistulizing Crohn's disease [PFCD]. This study evaluated the efficacy and safety of the Janus kinase 1…”
Get full text

Validation of the Polish version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) by Siuda, Joanna, Boczarska-Jedynak, Magdalena, Budrewicz, Sławomir, Dulski, Jarosław, Figura, Monika, Fiszer, Urszula, Gajos, Agata, Gorzkowska, Agnieszka, Koziorowska-Gawron, Ewa, Koziorowski, Dariusz, Krygowska-Wajs, Anna, Rudzińska-Bar, Monika, Sławek, Jarosław, Ren, Xuehan, Luo, Sheng, Martinez-Martin, Pablo, Stebbins, Glenn, Goetz, Christopher G, Opala, Grzegorz

“…In 2008, the Movement Disorders Society (MDS) published a new Unified Parkinson's Disease Rating Scale (MDS-UPDRS) as the official benchmark scale for…”
Get more information

Missing Data in the Unified Dysksinesia Rating Scale (UDysRS) by Luo, Sheng, Ren, Xuehan, Han, Weilu, Goetz, Christopher G., Stebbins, Glenn T.

“…ABSTRACT Objective Identify the number of allowable missing values still permitting valid surrogate score calculation for the Unified Dyskinesia Rating Scale…”
Get full text

Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1 by Hauser, Robert A, Li, Ruosha, Pérez, Adriana, Ren, Xuehan, Weintraub, Dan, Elm, Jordan, Goudreau, John L, Morgan, John C, Fang, John Y, Aminoff, Michael J, Christine, Chadwick W, Dhall, Rohit, Umeh, Chizoba C, Boyd, James T, Stover, Natividad, Leehey, Maureen, Zweig, Richard M, Nicholas, Anthony P, Bodis-Wollner, Ivan, Willis, Allison, Kieburtz, Karl, Tilley, Barbara C

“…Monoamine oxidase type B (MAO-B) inhibitors exhibit neuroprotective effects in preclinical models of PD but clinical trials have failed to convincingly…”
Get more information